Ipilimumab

Phase 1/2Terminated

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Very High Risk Prostate Carcinoma

Conditions

Very High Risk Prostate Carcinoma

Trial Timeline

Aug 25, 2025 → Mar 9, 2026

NCT ID

NCT06388369

About Ipilimumab

Ipilimumab is a phase 1/2 stage product being developed by Bristol Myers Squibb for Very High Risk Prostate Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT06388369. Target conditions include Very High Risk Prostate Carcinoma.

What happened to similar drugs?

2 of 5 similar drugs in Very High Risk Prostate Carcinoma were approved

Approved (2) Terminated (1) Active (2)

✅BAY207543 (Bepanthol, Bepantol® Derma Spray)BayerApproved

❌Roxadustat + PlaceboAstellas PharmaPhase 3

🔄Benralizumab Arm A + Benralizumab Arm B + PlaceboAstraZenecaPhase 3

🔄Benralizumab Arm A + Benralizumab Arm B + Benralizumab Arm C + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00495066	Pre-clinical	Completed	—	—	Melanoma
NCT06388369	Phase 1/2	Terminated	Aug 25, 2025	Mar 9, 2026	Very High Risk Prostate Carcinoma
NCT05074992	Phase 2	Terminated	Aug 24, 2022	May 2, 2023	Glioblastoma
NCT04635735	Phase 1/2	Terminated	Jan 12, 2020	Feb 2, 2023	Relapsed/Refractory Multiple Myeloma
NCT04196452	Pre-clinical	Active	Aug 12, 2019	Jul 24, 2034	Melanoma
NCT06566391	Phase 2	UNKNOWN	Mar 5, 2019	Dec 31, 2024	Melanoma
NCT02739386	Pre-clinical	Completed	Feb 29, 2016	Mar 30, 2017	Melanoma
NCT02516527	Phase 1	Completed	Oct 16, 2015	Sep 20, 2018	Melanoma
NCT02224768	Pre-clinical	Completed	Jul 1, 2015	Nov 1, 2015	Advanced Melanoma
NCT02279862	Phase 2	Completed	Dec 2, 2014	Dec 15, 2016	Prostate Cancer
NCT02107755	Phase 2	Completed	Sep 5, 2014	Aug 16, 2021	Liver Metastases
NCT02239900	Phase 1	Completed	Aug 26, 2014	Oct 25, 2019	Liver Cancer
NCT02113657	Phase 1	Completed	Aug 20, 2014	Nov 4, 2019	Prostate Cancer
NCT02221739	Phase 1/2	Completed	Jul 1, 2014	Oct 27, 2015	Non-small Cell Lung Cancer (NSCLC)
NCT02115139	Phase 2	Completed	Apr 4, 2014	Jul 31, 2018	Melanoma
NCT02050594	Pre-clinical	Completed	Feb 1, 2014	Feb 1, 2015	Melanoma
NCT01990859	Phase 2	Completed	Dec 1, 2013	Feb 1, 2015	Melanoma
NCT01696045	Phase 2	Terminated	Nov 12, 2012	Jul 31, 2016	Malignant Melanoma
NCT01703507	Phase 1	Completed	Nov 9, 2012	Apr 11, 2018	Recurrent Melanoma
NCT02662725	Phase 2	Completed	Sep 1, 2012	Dec 1, 2015	Melanoma

Competing Products

10 competing products in Very High Risk Prostate Carcinoma

See all competitors

Product	Company	Stage	Hype Score
Roxadustat + Placebo	Astellas Pharma	Phase 3	32
Benralizumab Arm A + Benralizumab Arm B + Placebo	AstraZeneca	Phase 3	40
Benralizumab Arm A + Benralizumab Arm B + Benralizumab Arm C + Placebo	AstraZeneca	Phase 3	40
Ruxolitinib	Novartis	Pre-clinical	26
Etavopivat	Novo Nordisk	Phase 2	27
BAY207543 (Bepanthol, Bepantol® Derma Spray)	Bayer	Approved	40
BAY207543 (Bepanthol, Bepantol® Derma Spray)	Bayer	Approved	40
triheptanoin	Ultragenyx Pharmaceutical	Pre-clinical	20
Chondrogen + Chondrogen + Placebo	Mesoblast	Phase 1/2	26
Mesenchymal Stem Cells + Hyaluronan	Mesoblast	Phase 1/2	26